https://www.selleckchem.com/pr....oducts/pembrolizumab
Overall survival (OS) and disease-free survival (DFS) was 82.2% and 77.8% respectively. Group wise OS was 75% in the malignant group, 82.6% in the immune dysregulation group, 80% in patients with metabolic disorders and bone marrow failure, while 100% in patients with bleeding diathesis. This retrospective analysis shows that hematopoietic stem cell transplant can be a feasible treatment option for rare hematological disorders.Affitins are a novel class of small 7 kDa artificial proteins which can be used as antibody substitutes i
Like
Comment
Share
